Advanced Course CTD module 3 - Quality section 2026
This advanced course focuses on Module 3 (Quality) of the Common Technical Document (CTD) and provides a structured, in-depth overview of quality requirements for both drug substances and drug products.
-
Day 1, Thursday, March 26
-
-
-
Registration & coffee
-
-
-
-
Welcome & Introduction to the course (Marc Benijts - Healixia)
-
-
-
-
Overview CTD – Quality related issues (Tinneke Pletinckx - FAMHP)
-
-
-
-
Relevant analytical techniques and method validation (Evelien Wynendaele - UGent)
-
-
-
-
Coffee break
-
-
-
-
Stability in the Pharmaceutical World (Tine Eelen - Johnson & Johnson Innovative Medicine)
-
-
-
-
Drug substance: general requirements (Thomas Drapier - FAMHP)
-
-
-
-
Lunch break
-
-
-
-
Drug substance: synthesis and control during synthesis (Michel Guillaume - Auxilis)
-
-
-
-
Drug substance: impurities (Quality aspects: Eddy Dolusic - FAMHP; Non-clinical aspects: Evelyne Pirotte - FAMHP)
-
-
-
-
Coffee break
-
-
-
-
Drug products: General overview and practical tips (Isabelle Delneuville - FAMHP)
-
-
-
-
Solid oral dosage forms (Charlotte Geleyn - UGent)
-
-
-
-
Parenteral dosage forms (Simon Degand - FAMHP)
-
-
Day 2, Friday, March 27
-
-
-
Variations according to Regulation EC 1234/2008 (Roselien Poppe - FAMHP)
-
-
-
-
Handling of Variations to Module 3 (Eline Van der Biest & Liesbeth Bogaert - FAMHP)
-
-
-
-
Variations: Theoretical & practical application worked out through several case studies - Introduction to the cases (Mixed panel FAMHP & Industry)
-
-
-
-
Coffee break
-
-
-
-
Work out of case studies in workshops (1) (Mixed panel FAMHP & Industry)
-
-
-
-
Lunch break
-
-
-
-
Work out of case studies in workshops (2) (Mixed panel FAMHP & Industry)
-
-
-
-
Coffee break
-
-
-
-
Work out of case studies in workshops (3) (Mixed panel FAMHP & Industry)
-
-
-
-
Closing Remarks (Marc Benijts - Healixia)
-